Drug Database · Medical nutrition (FSMP)

Nepro

Renal nutrition formula: LP (lower protein, CKD not on dialysis) and HP (higher protein, dialysis) variants

Medical nutrition (FSMP)Renal formulaHigher protein (HP)Lower protein (LP)13 registrations Kidney notes reviewed
Company: ABBOTT LABORATORIES Last updated: Audience: Licensed health professionals
Registered with the Philippine FDA as a FOOD FOR SPECIAL MEDICAL PURPOSES — for the dietary management of patients under medical supervision. Use with a physician's or dietitian's guidance; it is a food, not a drug.

Kidney notes

Nepro is a renal nutrition formula (ABBOTT LABORATORIES) registered with the Philippine FDA as a food for special medical purposes (FSMP), not as a drug or a food supplement. It comes in a lower-protein (LP) version for CKD not on dialysis and a higher-protein (HP) version for dialysis. Its job is to help a patient meet energy and protein targets when food alone falls short.

What each variant is for

  • Nepro HP: higher-protein version: for patients on dialysis, to help reach 1.0 to 1.2 g/kg/day when food alone falls short. Registered "for the dietary management of patients on dialysis".
  • Nepro LP: lower-protein version: for CKD not on dialysis; fit the formula's protein within a low-protein prescription (0.55 to 0.6 g/kg/day, or 0.6 to 0.8 g/kg/day with diabetes) and use it mainly to cover energy. Registered "for the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis".

How it fits the KDOQI 2020 nutrition guideline

  • Chronic kidney disease (CKD) stages 3 to 5, not on dialysis, metabolically stable, without diabetes: KDOQI 2020 recommends a low-protein diet of 0.55 to 0.6 g/kg body weight per day, or a very low-protein diet of 0.28 to 0.43 g/kg/day with ketoacid analogues, under close dietitian supervision. With diabetes the target is 0.6 to 0.8 g/kg/day.
  • Maintenance hemodialysis or peritoneal dialysis, metabolically stable: 1.0 to 1.2 g/kg body weight per day.
  • CKD stages 3 to 5 or on dialysis, at risk of or with protein-energy wasting (PEW): KDOQI suggests a minimum 3-month trial of oral nutritional supplements when dietary counseling alone does not reach energy and protein needs.
  • A renal formula is a tool for reaching these targets. The lower-protein (LP) version has to fit inside the daily protein allowance of a patient not on dialysis; the higher-protein (HP) version helps a dialysis patient reach the higher target. Neither replaces individualized counseling by a renal dietitian.

Evidence

  • Product-specific: a small randomized trial in 41 malnourished hemodialysis patients found serum albumin rose faster with intensive dietary counseling alone than with Nepro (Akpele 2004).
  • Product-specific: in a nonrandomized study of 88 hemodialysis patients, at least one can of Nepro with each session for 3 months kept serum albumin stable while it fell in the comparison group (Scott 2009).
  • Product-specific: a Thai randomized trial of 80 malnourished hemodialysis patients (30 days, with dietitian counseling in all arms) compared ONCE Dialyze, Nepro and no supplement; the malnutrition-inflammation score improved in both supplement arms, and serum albumin rose significantly only with ONCE Dialyze versus control (Limwannata 2021).
  • Cochrane review (Mah 2020): 22 randomized trials, 1,278 adults on dialysis. Oral protein-based supplements probably raise serum albumin (mean difference 0.19 g/dL, moderate certainty), more so on hemodialysis and in malnourished patients. Deaths were not reported as an outcome in any trial, so the effect on survival and other clinical outcomes is uncertain.
  • Meta-analysis (Liu 2023): 22 randomized trials, 1,185 patients on dialysis. Supplements raised serum albumin (1.26 g/L), body mass index and handgrip strength, with no significant change in serum phosphorus, potassium or C-reactive protein.
  • Renal-specific supplement trial (Fouque 2008): 86 hemodialysis patients with low intake randomized to a renal-specific oral supplement (another brand) for 3 months or standard care. Intake rose in the per-protocol analysis (not clearly in intention-to-treat), phosphate and binder use did not increase, and subjective global assessment and quality of life improved.
  • Observational data: in a large matched cohort of hypoalbuminemic hemodialysis patients, intradialytic supplements were associated with lower mortality (adjusted intention-to-treat hazard ratio 0.91, 95% CI 0.85 to 0.98), with residual confounding possible (Lacson 2012); a smaller disease-management cohort found fewer hospitalizations but no significant mortality difference (Cheu 2013).
  • Evidence for supplements in CKD not on dialysis is thinner: the trials above are in dialysis patients. In non-dialysis CKD, the formula's role is to cover energy needs while staying within a prescribed low-protein diet.

Cautions in kidney disease

  • Potassium, phosphorus and sodium: renal formulas are marketed as lower in these than standard formulas, but amounts differ by brand, variant and reformulation. Check the product label and count every serving in the day's potassium and phosphorus; monitor serum levels after starting.
  • Fluid: a ready-to-drink serving, or the water used to mix a powder, counts toward the interdialytic fluid allowance.
  • Variant mismatch: an HP (dialysis) version taken by a patient on a low-protein diet before dialysis adds protein beyond the prescription; an LP version on dialysis may not deliver enough protein.
  • Diabetes: these formulas contain carbohydrate. Check glucose after starting, especially with insulin or sulfonylureas, and use the diabetic protein target (0.6 to 0.8 g/kg/day) before dialysis.
  • Cost: these are paid out of pocket in most settings. Reserve them for patients with, or at risk of, protein-energy wasting, set a goal (intake, weight, albumin, subjective global assessment), and reassess after about 3 months.
  • A food for special medical purposes is meant for use under medical supervision; it supplements meals and does not replace them.

Bottom line

A reasonable choice for a patient with, or at risk of, protein-energy wasting whose intake falls short after dietitian counseling: match the variant to the stage (LP before dialysis, HP on dialysis), check the label for potassium, phosphorus and fluid, and reassess after about 3 months. Supplements raise albumin and intake; effects on survival are not proven by trials.

Sources

  1. Ikizler, T. A., Burrowes, J. D., Byham-Gray, L. D., Campbell, K. L., Carrero, J.-J., Chan, W., Fouque, D., Friedman, A. N., Ghaddar, S., Goldstein-Fuchs, D. J., Kaysen, G. A., Kopple, J. D., Teta, D., Yee-Moon Wang, A., & Cuppari, L. (2020). KDOQI clinical practice guideline for nutrition in CKD: 2020 update. American Journal of Kidney Diseases, 76(3 Suppl 1), S1–S107. https://doi.org/10.1053/j.ajkd.2020.05.006
  2. Mah, J. Y., Choy, S. W., Roberts, M. A., Desai, A. M., Corken, M., Gwini, S. M., & McMahon, L. P. (2020). Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews, 5(5), CD012616. https://doi.org/10.1002/14651858.CD012616.pub2
  3. Liu, P. J., Guo, J., Zhang, Y., Wang, F., & Yu, K. (2023). Effects of oral nutritional supplements on the nutritional status and inflammatory markers in patients on maintenance dialysis: A systematic review and meta-analysis of randomized clinical trials. Clinical Kidney Journal, 16(11), 2271–2288. https://doi.org/10.1093/ckj/sfad130
  4. Fouque, D., McKenzie, J., de Mutsert, R., Azar, R., Teta, D., Plauth, M., & Cano, N. (2008). Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrology Dialysis Transplantation, 23(9), 2902–2910. https://doi.org/10.1093/ndt/gfn131
  5. Lacson, E., Jr., Wang, W., Zebrowski, B., Wingard, R., & Hakim, R. M. (2012). Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: A quality improvement report. American Journal of Kidney Diseases, 60(4), 591–600. https://doi.org/10.1053/j.ajkd.2012.04.019
  6. Cheu, C., Pearson, J., Dahlerus, C., Lantz, B., Chowdhury, T., Sauer, P. F., Farrell, R. E., Port, F. K., & Ramirez, S. P. B. (2013). Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clinical Journal of the American Society of Nephrology, 8(1), 100–107. https://doi.org/10.2215/CJN.13091211
  7. Akpele, L., & Bailey, J. L. (2004). Nutrition counseling impacts serum albumin levels. Journal of Renal Nutrition, 14(3), 143–148. https://doi.org/10.1053/j.jrn.2004.04.003
  8. Scott, M. K., Shah, N. A., Vilay, A. M., Thomas, J., Kraus, M. A., & Mueller, B. A. (2009). Effects of peridialytic oral supplements on nutritional status and quality of life in chronic hemodialysis patients. Journal of Renal Nutrition, 19(2), 145–152. https://doi.org/10.1053/j.jrn.2008.08.004
  9. Limwannata, P., Satirapoj, B., Chotsriluecha, S., Thimachai, P., & Supasyndh, O. (2021). Effectiveness of renal-specific oral nutritional supplements compared with diet counseling in malnourished hemodialysis patients. International Urology and Nephrology, 53(8), 1675–1687. https://doi.org/10.1007/s11255-020-02768-5

Reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. renalcarematters.com, reviewed

Variants and registered use

LP and HP are the manufacturer's labels for the lower-protein and higher-protein versions, as registered. Per-serving protein, energy, potassium, phosphorus, sodium and fluid differ between versions and change with reformulation: check the product label.

VariantRegistered use FlavorFR numbers
HP · higher protein, for dialysisFor the dietary management of patients on dialysisVanillaFR-4000013041397 FR-2359149 FR-4000014820326 FR-4000012348396 FR-4000012473544 FR-4000008809377
LP · lower protein, for CKD not on dialysisFor the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysisVanillaFR-4000013060729 FR-2359787 FR-4000015266350 FR-4000013308957 FR-4000013030973 FR-4000012473889 FR-4000008828288

FDA Philippines registrations

13 current FSMP registrations under the brand Nepro. Registration status changes; confirm a product's current status on the FDA verification portal using its FR number.

Verify on PH FDA portal

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000013060729 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
May 20, 2025
Valid until
May 20, 2037
FDA risk class
High Risk
Application
Renewal

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES-FOR THE DIETARY MANAGEMENT OF PATIENTS ON DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000013041397 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients on dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
February 24, 2026
Valid until
May 20, 2037
FDA risk class
High Risk
Application
Amendment

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-2359787 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
August 20, 2026
Valid until
August 20, 2031
FDA risk class
High Risk
Application
Initial

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES-FOR THE DIETARY MANAGEMENT OF PATIENT ON DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-2359149 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patient on dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
August 7, 2026
Valid until
August 7, 2031
FDA risk class
High Risk
Application
Initial

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000015266350 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
October 20, 2025
Valid until
October 20, 2030
FDA risk class
High Risk
Application
Renewal Data Capture

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS ON DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000014820326 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients on dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
March 17, 2026
Valid until
August 29, 2030
FDA risk class
High Risk
Application
Automatic Amendment

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES-FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000013308957 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
September 10, 2024
Valid until
September 10, 2029
FDA risk class
High Risk
Application
Renewal

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000013030973 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
Not stated in the FDA record
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
August 22, 2024
Valid until
June 24, 2029
FDA risk class
High Risk
Application
Amendment

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000012348396 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
Not stated in the FDA record
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
March 31, 2026
Valid until
June 19, 2029
FDA risk class
High Risk
Application
Amendment

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000012473889 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
June 4, 2024
Valid until
June 4, 2029
FDA risk class
High Risk
Application
Initial

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS ON DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000012473544 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients on dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
January 23, 2026
Valid until
May 15, 2029
FDA risk class
High Risk
Application
Amendment

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 1-5 NOT REQUIRING DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000008828288 · verify on the FDA portal
Variant
LP · lower protein, for CKD not on dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients with chronic kidney disease (CKD) stages 1-5 not requiring dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
February 3, 2022
Valid until
February 3, 2027
FDA risk class
High Risk
Application
Initial

RENAL NUTRITION - VANILLA FLAVOR (FOOD FOR SPECIAL MEDICAL PURPOSES- FOR THE DIETARY MANAGEMENT OF PATIENTS ON DIALYSIS)

Composition

The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.

FR number
FR-4000008809377 · verify on the FDA portal
Variant
HP · higher protein, for dialysis
Registered as
Food for special medical purposes (FSMP)
Registered use
For the dietary management of patients on dialysis
Flavor
Vanilla
Form
Not stated in the FDA record
Company
ABBOTT LABORATORIES
Issued
February 3, 2022
Valid until
February 3, 2027
FDA risk class
High Risk
Application
Initial
For health professionals. Data come from the FDA Philippines food-product registration database and may lag behind the official record. A food-for-special-medical-purposes registration means the product may be sold as a food for the dietary management of patients under medical supervision; it is not a drug approval. Not a substitute for clinical judgment.